title: SIV DNA vaccine trial in macaques: post-challenge necropsy in vaccine and control groups.
abstract: In this study we describe the histopathologic findings from nine macaques in a simian immunodeficiency virus (SIV) DNA vaccine trial evaluating the ability of a 5-plasmid DNA vaccine to protect against an uncloned SIVmac251 challenge (Lu et al., J. Virol. 1996, 70, 3978-3991). Three vaccinated and one control macaque developed disease and were euthanized in the first year following challenge. The other four vaccinated and one control macaque remained clinically normal and were euthanized at the end of the trial (60 weeks post-challenge). The necropsy data revealed that both diseased and clinically normal macaques had developed typical SIV-related lymphoid changes, inflammatory disorders and opportunistic infections. All animals had variable degrees of follicular and/or paracortical lymphoid hyperplasia suggesting immune activation. All but one vaccinated macaque and both control macaques had SIV-associated opportunistic infections. Within the small groups of animals, the ability to contain opportunistic infections was superior, and the overall lymphoid changes less severe, in the macaques that had received vaccine DNAs by three routes of inoculation (intravenous, intramuscular and gene gun) than in those that had received control DNAs or vaccine DNAs by gene gun only. In the future it will be important to further test how the route and method of DNA inoculation impact the efficacy of immunodeficiency virus vaccines.
authors.affiliation: Department of Pathology, University of Massachusetts Medical Center, Worcester 01655, USA.
authors.forename: S
authors.initials: S
authors.lastname: Lu
authors.forename: K
authors.initials: K
authors.lastname: Manson
authors.forename: M
authors.initials: M
authors.lastname: Wyand
authors.forename: H L
authors.initials: HL
authors.lastname: Robinson
mesh_terms: D000818:Animals; D001344:Autopsy; D019470:Biolistics; D004279:DNA, Viral / Q000276:immunology; D015686:Gene Products, env / Q000235:genetics / Q000276:immunology; D008251:Macaca; D015682:Retroviridae Proteins, Oncogenic / Q000235:genetics / Q000276:immunology; D018449:SAIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000473:pathology / Q000517:prevention & control*; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*; D014760:Viral Fusion Proteins / Q000235:genetics / Q000276:immunology
chemical_list: D004279:DNA, Viral; D015686:Gene Products, env; D015682:Retroviridae Proteins, Oncogenic; D018449:SAIDS Vaccines; D019444:Vaccines, DNA; D014760:Viral Fusion Proteins; C059580:transmembrane protein, Simian immunodeficiency virus